Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

Bakirtas M., Dal M. S., Yigenoglu T. N., Giden A. O., Serin I., Basci S., ...More

JOURNAL OF CHEMOTHERAPY, vol.35, no.6, pp.563-569, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 6
  • Publication Date: 2023
  • Doi Number: 10.1080/1120009x.2023.2208439
  • Journal Name: JOURNAL OF CHEMOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.563-569
  • Keywords: proteasome inhibitors, ixazomib, lenalidomide, multiple myeloma, Turkey, multicenter, PROTEASOME INHIBITOR MLN9708, ORAL IXAZOMIB, ANTITUMOR-ACTIVITY, EFFICACY, TRANSPLANTATION, COMBINATION, MODELS, CELL
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients.